ESBL Pyelonephritis With Sepsis and Penicillin Anaphylaxis
A 72-year-old woman with type 2 diabetes and a history of recurrent urinary tract infections presents with 2 days of fever, flank pain, and confusion. Temperature 38.9°C, blood pressure 95/60 mmHg, pulse 112/min. WBC 18,000/µL, creatinine 1.9 mg/dL (baseline 1.0). Urine culture grew Escherichia coli resistant to ceftriaxone and ciprofloxacin and susceptible to meropenem, ertapenem, amikacin, and nitrofurantoin. Blood cultures are pending. She has a documented anaphylactic reaction to penicillin. The team is considering oral nitrofurantoin, continued ceftriaxone, or a carbapenem.
1. Select an appropriate antibiotic regimen and justify it using the susceptibility data, infection site, and allergy history. Address the carbapenem allergy concern.
Read the worked answer
The infection is pyelonephritis with sepsis in a patient with ESBL-producing E. coli resistant to ceftriaxone and ciprofloxacin. Nitrofurantoin is inappropriate because it concentrates in urine and does not achieve reliable renal tissue or blood levels; it is for cystitis, not pyelonephritis. Ceftriaxone is resistant and unreliable for ESBL organisms. A carbapenem (meropenem IV for severe sepsis, or ertapenem if less severe) is the appropriate choice based on susceptibility. The penicillin anaphylaxis history raises a practical concern, but carbapenem cross-reactivity with penicillin is low, generally under 1%; with a severe reaction, involve allergy/immunology, document the reaction, and consider carbapenem allergy testing or a monitored first dose. Amikacin is active but nephrotoxic with creatinine 1.9, so it is a secondary option. Do not use nitrofurantoin.
2. Explain why nitrofurantoin and ceftriaxone are poor choices here even if the laboratory reports susceptible for nitrofurantoin. What pharmacokinetic principle applies?
Read the worked answer
Nitrofurantoin's susceptible result reflects achievable urinary concentrations, not plasma or tissue concentrations. Pyelonephritis requires effective drug levels in renal parenchyma and blood, so a urinary antiseptic can fail despite a susceptible report. Ceftriaxone is explicitly resistant; ESBL enzymes hydrolyze third-generation cephalosporins, and even a laboratory susceptible result can be misleading because of inoculum effects and poor clinical response. The relevant principle is pharmacokinetics/pharmacodynamics at the site of infection: tissue penetration, protein binding, and the probability of maintaining free drug above the MIC. For sepsis, source control and adequate systemic coverage matter more than urinary sterilization.
3. Blood cultures return negative at 48 hours and the patient improves. What stewardship step is appropriate? What oral options would you consider if susceptibility were available?
Read the worked answer
If blood cultures are negative at 48 hours and the patient is improving, de-escalate to the narrowest effective regimen and set a planned duration, typically 7–14 days for pyelonephritis with bacteremia depending on response. For ESBL E. coli, oral options are limited; use a fluoroquinolone only if susceptible (not here), trimethoprim-sulfamethoxazole if susceptible, or continue an ertapenem-based outpatient parenteral regimen. Nitrofurantoin and fosfomycin are not appropriate for pyelonephritis. Remove unnecessary central lines, review renal function, and avoid prolonged broad-spectrum therapy. The stewardship judgment is to treat the infection adequately while not continuing meropenem automatically for the full course if a narrower option exists.